Early identification and timely treatment of substance use disorder (SUD) in pregnancy is a priority for women, families, clinicians and society. Common goals include prevention of illness progression, education regarding best care practices, and improved access to comprehensive treatment. Provision of compassionate care includes appropriate pharmacotherapy as well as safeguards against discrimination and stigmatization. Validation of this care model and approach through research will help build a stronger evidence base for effective policies and care delivery strategies in the future. As the social and health repercussions of SUD during pregnancy grow heavier, necessary interventions along the continuum of prenatal and postpartum care are gaining in urgency for programming, policy and research focus.
The panel will discuss substance use disorder treatment during pregnancy and in the postpartum period. Evidence-based management approaches for opioid use disorder, benzodiazepine use disorder, contraceptive practices, and overdose prevention will be provided. Perinatal, postpartum, neonatal, public health and research perspectives will be condensed, with the aim to translate data into a practical clinical guide.
Mishka Terplan will discuss maternal mortality and overdose prevention through a public health lens highlighting fatal and non-fatal postpartum overdose in relationship to pharmacotherapy, and provide suggestions for improving postpartum and lifecourse care.
Hendree Jones will present research data on contraception practices and address induction techniques for treating pregnant and parenting women with buprenorphine.
Tricia Wright will discuss buprenorphine dosing in pregnancy and beyond, with focus on pharmacokinetics and evidence-based recommendations in the prenatal and postpartum care.
Vania Rudolf and Jim Walsh will address challenges and practical considerations for benzodiazepine use disorder and summarize treatment benefits for optimizing maternal and neonatal outcomes.